Stay updated on Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:26:17.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the progression free survival (PFS) rate at 6 months for patients in a Phase II trial of Fruquintinib with Sintilimab treating refractory metastatic colorectal cancer patients with TMB-High and Non-MSI-High conditions.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:31.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as understanding the study, signing the Informed Consent Form, and having a histologically or cytologically diagnosed metastatic colorectal adenocarcinoma. Previously, this section had no information provided.
    Difference
    40%
    Check dated 2024-05-22T21:38:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:27:47.000Z thumbnail image

Stay in the know with updates to Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib-Sintilimab Combo in Refractory CRC Clinical Trial page.